1197-18-8
1197-18-8
Chemical Structure
Tranexamic acid
Synonym(s): cyclocapron
- CAS No.: 1197-18-8
- Formula:C8H15NO2
- Molecular Weight:157.21
IUPAC Name: (1r,4r)-4-(aminomethyl)cyclohexane-1-carboxylic acid
InChIKey: GYDJEQRTZSCIOI-LJGSYFOKSA-N
SMILES: O=C([C@H]1CC[C@H](CN)CC1)O
Biological Activity: Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis. Tranexamic acid is a PROTAC linker. Tranexamic acid is used to synthesize PROTACs (e.g. LZ-07 (HY-172590))[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tranexamic acid | 99.88% | Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis. Tranexamic acid is a PROTAC linker. Tranexamic acid is used to synthesize PROTACs (e.g. LZ-07 (HY-172590)). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tranexamic acid (Standard) | 99.91% | Tranexamic acid (Standard) is the analytical standard of Tranexamic acid. This product is intended for research and analytical applications. Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tranexamic acid-13C6 | Tranexamic acid-13C6 (Cyclocapron-13C6) is 13C labeled Tranexamic acid. Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis . | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tranexamic acid-d2-1 | 98.72% | Tranexamic acid-d2-1 is the deuterium labeled Tranexamic acid. Tranexamic acid (Transamin) is an antifibrinolytic for blocking lysine-binding sites of plasmin and elastase-derived plasminogen fragments with IC50 of 5 mM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tranexamic acid-13C2,15N | Tranexamic acid-13C2,15N (Cyclocapron-13C2,15N) is the 13C2 and 15N labeled Tranexamic acid. Tranexamic acid is an antifibrinolytic agent that alleviates liver damage and fibrosis in mouse models of chronic bile duct injury. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Prudovsky I, et al. Tranexamic acid suppresses the release of mitochondrial DNA, protects the endothelial monolayer and enhances oxidative phosphorylation [J]. Journal of cellular physiology, 2019, 234(11): 19121-19129. [Content Brief]
- [2]. Wu G, et al. Tranexamic acid is an active site inhibitor of urokinase plasminogen activator [J]. Blood advances, 2019, 3(5): 729-733. [Content Brief]
- [3]. Draxler D F, et al. Tranexamic acid modulates the cellular immune profile after traumatic brain injury in mice without hyperfibrinolysis [J]. Journal of Thrombosis and Haemostasis, 2019, 17(12): 2174-2187. [Content Brief]
- [4]. Hiramoto K, et al. The amelioration effect of tranexamic acid in wrinkles induced by skin dryness [J]. Biomedicine & Pharmacotherapy, 2016, 80: 16-22. [Content Brief]
- [5]. Sindet-Pedersen S, et al. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery [J]. New England Journal of Medicine, 1989, 320(13): 840-843. [Content Brief]
- [6]. Zhen Li, et al., Developing potent anti-inflammatory IRAK4-targeting PROTACs with simplified CRBN ligands, Chinese Chemical Letters, 2025, 111033, ISSN 1001-8417.
